TherapeuticsMD Company Profile (NYSEMKT:TXMD)

About TherapeuticsMD (NYSEMKT:TXMD)

TherapeuticsMD logoTherapeuticsMD, Inc. is a women's healthcare company engaged in creating and commercializing products for women. The Company is focused on pursuing regulatory approvals and pre-commercialization activities necessary for commercialization of its hormone therapy pharmaceutical products. Its drug candidates used in clinical trials are designed to alleviate symptoms of and reduce health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis and vaginal discomfort. With its SYMBODA technology, it is developing hormone therapy pharmaceutical products to enable delivery of bio-identical hormones through dosage forms and administration routes. Its product line includes vitaTrue, vitaPearl, vitaMedMD Plus, vitaMedMD One Prenatal Multivitamin, vitaMedMD Plus Rx Prenatal Multivitamin, vitaMedMD One Rx Prenatal Multivitamin, vitaMedMD Iron 21/7, vitaMedMD Vitamin D3 50,000 IU, BocaGreenMD Prena1 Pearl and BocaGreenMD Prena1 Chew.

Industry, Sector and Symbol: Capitalization:
  • Market Cap: $1.04 billion
  • Outstanding Shares: 204,027,000
Average Prices:
  • 50 Day Moving Avg: $4.86
  • 200 Day Moving Avg: $4.86
  • 52 Week Range: $4.54 - $5.35
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -15.45
  • P/E Growth: -0.73
Sales & Book Value:
  • Annual Revenue: $18.26 million
  • Price / Sales: 56.98
  • Book Value: $0.46 per share
  • Price / Book: 11.09
  • EBITDA: ($88,990,000.00)
  • Net Margins: -462.94%
  • Return on Equity: -77.41%
  • Return on Assets: -68.24%
  • Average Volume: 2.62 million shs.
  • Short Ratio: 24.24

Frequently Asked Questions for TherapeuticsMD (NYSEMKT:TXMD)

What is TherapeuticsMD's stock symbol?

TherapeuticsMD trades on the New York Stock Exchange (NYSE)MKT under the ticker symbol "TXMD."

How were TherapeuticsMD's earnings last quarter?

TherapeuticsMD Inc (NYSEMKT:TXMD) announced its quarterly earnings data on Thursday, November, 3rd. The company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.11) by $0.02. The company had revenue of $5.50 million for the quarter, compared to analysts' expectations of $5.76 million. TherapeuticsMD had a negative net margin of 462.94% and a negative return on equity of 77.41%. The company's quarterly revenue was up 5.8% compared to the same quarter last year. During the same period last year, the business earned ($0.11) earnings per share. View TherapeuticsMD's Earnings History.

Where is TherapeuticsMD's stock going? Where will TherapeuticsMD's stock price be in 2017?

7 brokerages have issued 1-year target prices for TherapeuticsMD's stock. Their forecasts range from $6.00 to $33.00. On average, they anticipate TherapeuticsMD's stock price to reach $18.93 in the next year. View Analyst Ratings for TherapeuticsMD.

Who are some of TherapeuticsMD's key competitors?

Who are TherapeuticsMD's key executives?

TherapeuticsMD's management team includes the folowing people:

  • Tommy G. Thompson J.D., Independent Chairman of the Board
  • John C. K. Milligan IV, President, Secretary, Director
  • Robert G. Finizio, Chief Executive Officer, Director
  • Daniel A. Cartwright, Chief Financial Officer, Treasurer
  • Mitchell L. Krassan, Executive Vice President, Chief Strategy Officer
  • Michael Donegan, Vice President - Finance
  • Brian Bernick M.D., Chief Clinical Officer, Director
  • Jules A. Musing, Director
  • J. Martin Carroll, Independent Director
  • Cooper C. Collins, Independent Director

How do I buy TherapeuticsMD stock?

Shares of TherapeuticsMD can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is TherapeuticsMD's stock price today?

One share of TherapeuticsMD stock can currently be purchased for approximately $5.10.

MarketBeat Community Rating for TherapeuticsMD (NYSEMKT TXMD)
Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  202 (Vote Outperform)
Underperform Votes:  103 (Vote Underperform)
Total Votes:  305
MarketBeat's community ratings are surveys of what our community members think about TherapeuticsMD and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for TherapeuticsMD (NYSEMKT:TXMD) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Hold Rating, 6 Buy Ratings
Consensus Rating:Buy (Score: 2.86)
Consensus Price Target: $18.93
Consensus Price Target History for TherapeuticsMD (NYSEMKT:TXMD)
Price Target History for TherapeuticsMD (NYSEMKT:TXMD)
Analysts' Ratings History for TherapeuticsMD (NYSEMKT:TXMD)
DateFirmActionRatingPrice TargetDetails
9/8/2017Morgan StanleyInitiated CoverageEqual Weight$6.00View Rating Details
7/11/2017Oppenheimer Holdings, Inc.UpgradeMarket Perform -> OutperformView Rating Details
5/25/2017Stifel NicolausReiterated RatingBuy$20.00View Rating Details
5/11/2017Cantor FitzgeraldReiterated RatingOverweight$33.00View Rating Details
3/2/2017Jefferies Group LLCReiterated RatingBuy$18.00View Rating Details
12/6/2016GuggenheimReiterated RatingPositiveView Rating Details
12/4/2016Goldman Sachs Group, Inc. (The)Reiterated RatingBuy$10.50View Rating Details
7/11/2016Noble FinancialReiterated RatingBuy$17.50View Rating Details
(Data available from 10/21/2015 forward)


Earnings History for TherapeuticsMD (NYSEMKT:TXMD)
Earnings by Quarter for TherapeuticsMD (NYSEMKT:TXMD)
Earnings History by Quarter for TherapeuticsMD (NYSEMKT TXMD)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/23/2017Q416($0.12)($0.12)$5.91 million$4.49 millionViewListenView Earnings Details
11/3/2016Q316($0.11)($0.13)$5.76 million$5.50 millionViewN/AView Earnings Details
8/4/2016Q216($0.10)($0.11)$5.63 million$4.40 millionViewN/AView Earnings Details
5/3/2016Q116($0.09)($0.11)$5.73 million$4.93 millionViewN/AView Earnings Details
2/25/2016Q415($0.10)($0.10)$5.33 million$5.63 millionViewListenView Earnings Details
11/4/2015Q315($0.12)($0.11)$5.01 million$5.19 millionViewN/AView Earnings Details
8/6/2015Q215($0.11)($0.16)$4.65 million$4.80 millionViewListenView Earnings Details
5/5/2015($0.10)($0.13)ViewN/AView Earnings Details
3/10/2015Q414($0.09)($0.10)$2.86 million$4.26 millionViewN/AView Earnings Details
11/6/2014Q3 14($0.08)($0.12)ViewN/AView Earnings Details
5/6/2014Q1 14($0.06)($0.06)$3.08 million$2.80 millionViewN/AView Earnings Details
3/3/2014Q213($0.06)($0.06)$2.72 million$2.90 millionViewN/AView Earnings Details
5/8/2013Q113($0.06)($0.06)$1.32 million$1.50 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for TherapeuticsMD (NYSEMKT:TXMD)
Current Year EPS Consensus Estimate: $-0.44 EPS
Next Year EPS Consensus Estimate: $-0.33 EPS


Dividend History for TherapeuticsMD (NYSEMKT:TXMD)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for TherapeuticsMD (NYSEMKT:TXMD)
Insider Trades by Quarter for TherapeuticsMD (NYSEMKT:TXMD)
Institutional Ownership by Quarter for TherapeuticsMD (NYSEMKT:TXMD)
Insider Trades by Quarter for TherapeuticsMD (NYSEMKT:TXMD)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
3/11/2016Cooper C CollinsDirectorBuy16,000$6.23$99,680.00View SEC Filing  
8/25/2015Angus C RussellDirectorBuy13,500$5.98$80,730.00View SEC Filing  
6/8/2015Mitchell KrassanEVPSell30,000$8.18$245,400.00View SEC Filing  
5/12/2015Angus C RussellDirectorBuy35,000$6.15$215,250.00View SEC Filing  
5/11/2015Tommy G ThompsonChairmanBuy6,000$6.09$36,540.00View SEC Filing  
5/8/2015J Martin CarrollDirectorBuy10,000$6.11$61,100.00View SEC Filing  
11/21/2014Daniel A CartwrightCFOSell40,000$3.91$156,400.00View SEC Filing  
9/4/2014Tommy G ThompsonDirectorBuy1,757$5.44$9,558.08View SEC Filing  
6/5/2014Cooper C CollinsDirectorBuy20,000$3.84$76,800.00View SEC Filing  
5/9/2014Robert Lapenta, Jr.DirectorBuy5,000$3.66$18,300.00View SEC Filing  
5/8/2014Tommy ThompsonDirectorBuy14,000$3.57$49,980.00View SEC Filing  
3/26/2014Brian BernickDirectorSell421,268$6.70$2,822,495.60View SEC Filing  
3/26/2014John C.K. Iv MilliganInsiderSell353,412$6.70$2,367,860.40View SEC Filing  
3/26/2014Robert FinizioCEOSell982,053$6.70$6,579,755.10View SEC Filing  
3/10/2014Mitchell KrassanEVPSell7,500$7.73$57,975.00View SEC Filing  
2/26/2014John C.K. Iv MilliganPresidentSell25,000$6.31$157,750.00View SEC Filing  
2/21/2014Robert FinizioCEOSell50,000$6.17$308,500.00View SEC Filing  
2/12/2014Brian BernickDirectorSell31,250$6.16$192,500.00View SEC Filing  
1/30/2014John C.K. Iv MilliganInsiderSell25,000$6.16$154,000.00View SEC Filing  
1/23/2014Robert G FinizioCEOSell50,000$5.70$285,000.00View SEC Filing  
1/13/2014Mitchell KrassanEVPSell7,500$5.73$42,975.00View SEC Filing  
1/8/2014Brian BernickDirectorSell31,250$5.13$160,312.50View SEC Filing  
8/26/2013Brian BernickInsiderSell1,600,000$1.55$2,480,000.00View SEC Filing  
8/26/2013Jules A MusingDirectorBuy5,282$2.15$11,356.30View SEC Filing  
6/14/2013Cooper C CollinsDirectorSell2,631,579$1.75$4,605,263.25View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for TherapeuticsMD (NYSEMKT:TXMD)
Latest Headlines for TherapeuticsMD (NYSEMKT:TXMD)
DateHeadline logoTherapeuticsMD Inc (TXMD) Lowered to Strong Sell at BidaskClub - October 14 at 12:36 AM logoTherapeuticsMD Inc (TXMD) Receives Consensus Recommendation of "Buy" from Brokerages - October 12 at 8:08 AM logoTherapeuticsMD CEO on the switch to Nasdaq from NYSE - October 10 at 7:47 AM logoETFs with exposure to TherapeuticsMD, Inc. : October 9, 2017 - October 10 at 7:47 AM logoTherapeuticsMD Announces Pricing of Common Stock Offering - September 29 at 12:25 PM logoTherapeuticsMD, FDA Review for TX-004HR is Upcoming, Stock Shows Momentum - September 19 at 8:56 AM logoTherapeuticsMD Inc (TXMD) Receives Consensus Rating of "Buy" from Brokerages - September 17 at 8:40 AM logoTherapeuticsMD (TXMD) Submits Additional Endometrial Safety Information to NDA for TX-004HR - - September 15 at 10:31 AM logoTherapeuticsMD Announces Submission of Additional Endometrial Safety Information to the New Drug Application for TX-004HR - September 15 at 10:31 AM logoOptions Traders Expect Huge Moves in TherapeuticsMD (TXMD) Stock - September 14 at 11:52 AM logoOptions Traders Expect Huge Moves in TherapeuticsMD (TXMD) Stock - September 14 at 11:52 AM logoTherapeuticsMD Inc (TXMD) Receives New Coverage from Analysts at Morgan Stanley - September 8 at 1:16 PM logoTechnical Reports on Drug Makers Equities -- Impax Labs, GlaxoSmithKline, Novartis, and TherapeuticsMD - August 29 at 9:08 AM logoImplied Volatility Surging for TherapeuticsMD, Inc. (TXMD) Stock Options - August 23 at 1:07 PM logoTherapeuticsMD Inc (TXMD) Given Average Rating of "Buy" by Analysts - August 23 at 8:37 AM logoTherapeuticsMD (TXMD) Catches Eye: Stock Moves 5.9% Higher - Nasdaq - August 20 at 1:23 PM logoTherapeuticsMD (TXMD) Catches Eye: Stock Moves 5.9% Higher - Yahoo Finance - August 19 at 8:33 AM logoTherapeuticsMD (TXMD) Catches Eye: Stock Moves 5.9% Higher - August 18 at 8:13 AM logoToday's Research Reports on Stocks to Watch: TherapeuticsMD Inc. and Horizon Pharma - August 18 at 8:13 AM logoTherapeuticsMD (TXMD) Reports Publication of Manuscript on Women's Health Initiative Observational Study of ... - - August 17 at 8:46 AM logoTherapeuticsMD Announces Publication of Manuscript on the Women’s Health Initiative Observational Study of Vaginal Estrogen Use in Postmenopausal Women - August 17 at 8:45 AM logoSee what the IHS Markit Score report has to say about TherapeuticsMD Inc. - August 14 at 8:01 AM logoTherapeuticsMD (TXMD) Issue Update on TX-004HR, Says FDA ... - - August 11 at 9:04 AM logoTherapeuticsMD (TXMD) Issue Update on TX-004HR, Says FDA Requested Additional Info on or Before Sept. 18, Tentative Meeting Set for Nov. 3 - August 11 at 9:04 AM logoIHS Markit Score Update: Drop in demand for ETFs holding TherapeuticsMD Inc is a negative sign for its shares - August 10 at 9:04 AM logoEdited Transcript of TXMD earnings conference call or presentation 3-Aug-17 8:30pm GMT - August 5 at 8:02 AM logoInvestor Network: TherapeuticsMD, Inc. to Host Earnings Call - August 4 at 9:27 AM logoTherapeuticsMD Announces Second Quarter 2017 Financial Results - August 4 at 9:27 AM logoTherapeuticsMD Inc (TXMD) Given Average Recommendation of "Buy" by Brokerages - July 29 at 8:39 AM logoETFs with exposure to TherapeuticsMD, Inc. : July 25, 2017 - July 26 at 9:20 AM logoTherapeuticsMD to Host Second Quarter Financial Results Conference Call and Webcast on August 3 - July 21 at 8:12 AM logoTechnical Reports on Drug Makers Equities -- TherapeuticsMD, GlaxoSmithKline, Novartis, and Impax Labs - July 20 at 9:13 AM logoCantor Remains Bullish on TherapeuticsMD Inc (TXMD) as Investors Await Clarity on TX-004 - July 18 at 9:23 AM logo20 Stocks Moving In Monday's Pre-Market Session - Benzinga - July 17 at 9:14 AM logoTherapeuticsMD (TXMD) Announces Regulatory Update Regarding NDA for TX-004HR - - July 17 at 9:14 AM logoETFs with exposure to TherapeuticsMD, Inc. : July 14, 2017 - July 14 at 9:31 PM logoWhy TherapeuticsMD Inc Is Soaring Today - July 12 at 8:31 AM logoToday's Research Reports on Stocks to Watch: TherapeuticsMD, Inc. and Moleculin Biotech, Inc. - July 12 at 8:31 AM logoTherapeuticsMD Inc (TXMD) Raised to "Outperform" at Oppenheimer Holdings, Inc. - July 11 at 1:46 PM logoBurns J W & Co Inc Buys Amgen Inc, SPDR S&P Dividend, Vanguard REIT ETF - DNQ, Sells ... - July 8 at 3:01 PM logoTherapeuticsMD, Inc. breached its 50 day moving average in a Bearish Manner : TXMD-US : July 7, 2017 - July 8 at 3:01 PM logoTherapeuticsMD Inc (TXMD) Given Consensus Rating of "Buy" by Brokerages - July 4 at 8:16 AM logoStocks Under Scanner in the Drug Makers Space -- TherapeuticsMD ... - June 17 at 6:55 AM logoSHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in ... - PR Newswire (press release) - June 17 at 6:55 AM logoIMPORTANT THERAPEUTICSMD, INC. INVESTOR REMINDER: Wolf Haldenstein Adler ... - May 26 at 8:04 AM logoSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of TherapeuticsMD, Inc ... - PR Newswire (press release) - May 11 at 2:35 AM logoHere's Why TherapeuticsMD Inc. Stock Is Sinking Today - Motley Fool - May 9 at 7:54 PM logoHere's Why TherapeuticsMD Inc. Stock Is Sinking Today - May 8 at 1:43 PM logoTherapeuticsMD (TXMD) Receives CRL from FDA for TX-004HR NDA - - May 8 at 9:33 AM logoTXMD All Set For D-day, IMMU Soars On Strategic Plan, CTSO On Watch - Nasdaq - May 7 at 9:56 PM



TherapeuticsMD (TXMD) Chart for Saturday, October, 21, 2017

This page was last updated on 10/21/2017 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.